Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

Lisa V.E. Oostenbrink; Cornelia M. Jol-van der Zijde; Anja M. Jansen-Hoogendijk; Emma S. Pool; Astrid G.S. van Halteren; Dirk Jan A.R. Moes; Robbert G.M. Bredius; Alex B. Mohseny; Frans J.W. Smiers; Maarten J.D. van Tol; Marco W. Schilham; Arjan C. Lankester

doi:10.1016/j.hemonc.2019.12.003

Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

Lisa V.E. Oostenbrink
, Cornelia M. Jol-van der Zijde
, Anja M. Jansen-Hoogendijk
, Emma S. Pool
, Astrid G.S. van Halteren
, Dirk Jan A.R. Moes
, Robbert G.M. Bredius
, Alex B. Mohseny
, Frans J.W. Smiers
, Maarten J.D. van Tol
, Marco W. Schilham
, Arjan C. Lankester

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.

Original language	English
Pages (from-to)	61-65
Number of pages	5
Journal	Hematology/ Oncology and Stem Cell Therapy
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/j.hemonc.2019.12.003
Publication status	Published - Jun 2020
Externally published	Yes

Keywords

ATG
Grafalon
Haploidentical HSCT
Pediatrics
Sickle cell disease
Thymoglobulin

Access to Document

10.1016/j.hemonc.2019.12.003

Fingerprint

Dive into the research topics of 'Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?'. Together they form a unique fingerprint.

Cite this

Oostenbrink, L. V. E., Jol-van der Zijde, C. M., Jansen-Hoogendijk, A. M., Pool, E. S., van Halteren, A. G. S., Moes, D. J. A. R., Bredius, R. G. M., Mohseny, A. B., Smiers, F. J. W., van Tol, M. J. D., Schilham, M. W., & Lankester, A. C. (2020). Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation? Hematology/ Oncology and Stem Cell Therapy, 13(2), 61-65. https://doi.org/10.1016/j.hemonc.2019.12.003

Oostenbrink, Lisa V.E. ; Jol-van der Zijde, Cornelia M. ; Jansen-Hoogendijk, Anja M. et al. / Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany : What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?. In: Hematology/ Oncology and Stem Cell Therapy. 2020 ; Vol. 13, No. 2. pp. 61-65.

@article{a15e0278b065461d9f4153b3ce1b3263,

title = "Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?",

abstract = "Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.",

keywords = "ATG, Grafalon, Haploidentical HSCT, Pediatrics, Sickle cell disease, Thymoglobulin",

author = "Oostenbrink, \{Lisa V.E.\} and \{Jol-van der Zijde\}, \{Cornelia M.\} and Jansen-Hoogendijk, \{Anja M.\} and Pool, \{Emma S.\} and \{van Halteren\}, \{Astrid G.S.\} and Moes, \{Dirk Jan A.R.\} and Bredius, \{Robbert G.M.\} and Mohseny, \{Alex B.\} and Smiers, \{Frans J.W.\} and \{van Tol\}, \{Maarten J.D.\} and Schilham, \{Marco W.\} and Lankester, \{Arjan C.\}",

note = "Publisher Copyright: {\textcopyright} 2020 King Faisal Specialist Hospital \& Research Centre",

year = "2020",

month = jun,

doi = "10.1016/j.hemonc.2019.12.003",

language = "English",

volume = "13",

pages = "61--65",

journal = "Hematology/ Oncology and Stem Cell Therapy",

issn = "1658-3876",

publisher = "Wolters Kluwer Health",

number = "2",

}

Oostenbrink, LVE, Jol-van der Zijde, CM, Jansen-Hoogendijk, AM, Pool, ES, van Halteren, AGS, Moes, DJAR, Bredius, RGM, Mohseny, AB, Smiers, FJW, van Tol, MJD, Schilham, MW & Lankester, AC 2020, 'Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?', Hematology/ Oncology and Stem Cell Therapy, vol. 13, no. 2, pp. 61-65. https://doi.org/10.1016/j.hemonc.2019.12.003

Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation? / Oostenbrink, Lisa V.E.; Jol-van der Zijde, Cornelia M.; Jansen-Hoogendijk, Anja M. et al.
In: Hematology/ Oncology and Stem Cell Therapy, Vol. 13, No. 2, 06.2020, p. 61-65.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany

T2 - What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

AU - Oostenbrink, Lisa V.E.

AU - Jol-van der Zijde, Cornelia M.

AU - Jansen-Hoogendijk, Anja M.

AU - Pool, Emma S.

AU - van Halteren, Astrid G.S.

AU - Moes, Dirk Jan A.R.

AU - Bredius, Robbert G.M.

AU - Mohseny, Alex B.

AU - Smiers, Frans J.W.

AU - van Tol, Maarten J.D.

AU - Schilham, Marco W.

AU - Lankester, Arjan C.

PY - 2020/6

Y1 - 2020/6

N2 - Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.

AB - Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.

KW - ATG

KW - Grafalon

KW - Haploidentical HSCT

KW - Pediatrics

KW - Sickle cell disease

KW - Thymoglobulin

UR - https://www.scopus.com/pages/publications/85082193858

U2 - 10.1016/j.hemonc.2019.12.003

DO - 10.1016/j.hemonc.2019.12.003

M3 - Article

C2 - 32202242

AN - SCOPUS:85082193858

SN - 1658-3876

VL - 13

SP - 61

EP - 65

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

IS - 2

ER -

Oostenbrink LVE, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Pool ES, van Halteren AGS, Moes DJAR et al. Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation? Hematology/ Oncology and Stem Cell Therapy. 2020 Jun;13(2):61-65. doi: 10.1016/j.hemonc.2019.12.003